Mode
Text Size
Log in / Sign up
N/A N=160 Randomized Prevention

Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women

Depression, Postpartum

Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Proportion Sustainment of Core Program Elements — 0.34; 0.18; 0.43; 0.13 proportion of sessions — p=.12

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
EIAU (Behavioral); LICF (Behavioral); HICF (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Michigan State University
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion Sustainment of Core Program Elements
0.34; 0.18; 0.43; 0.13 .12
PRIMARY
Number of Months of Sustained ROSE Delivery
7.00; 5.07; 7.11; 3.38 .39
PRIMARY
Number of Months of Sustained ROSE Delivery With Fidelity
6.02; 4.41; 6.68; 2.20 .42
SECONDARY
Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months
1.07; 0.46; 1.62; 0 .51
SECONDARY
Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months
0.10; 0.06; 0.38; 0 .51

Summary

Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings. ROSE has been found to significantly reduce cases of PPD in multiple randomized trials in community prenatal settings with racially and ethnically diverse low-income pregnant women. Requests for ROSE training and recent policy changes supporting payment for comprehensive perinatal services to underserved populations suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for return on investment studies about sustainment efforts, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance in 6 U.S. states. In Year 1, all clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). At the first time at which a clinic is determined to be at risk for failure to sustain (i.e., at 3, 6, 9, 12, 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (i.e., EIAU only), or (2) low-intensity coaching and feedback (LICF). If clinics receiving LICF are still found to be at risk at subsequent assessments, they will be randomized to either (1) EIAU + LICF only, or (2) high-intensity coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. Outcomes include: 1. Sustainment of core program elements at each time point and total length of time ROSE services were provided and were provided with at least moderate fidelity. 2. Health impact (PPD rates over time at each clinic) and reach. 3. ROI (costs, cost-offsets, and cost-effectiveness) of each sustainment step. Hypothesized mechanisms include sustainment of clinical and organizational capacity to deliver core elements, and engagement/ownership. The study will also examine predictors, tailoring variables, and implementation processes to determine which kinds of clinics need which level of sustainment support and when. To our knowledge, this study will be the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science.

Eligibility Criteria

Study enrollment began with enrollment of clinics. Inclusion criteria for clinics were:

  • outpatient,
  • provide prenatal services,
  • estimate at least 30% of their pregnant patients received some kind of public assistance (such as federal or state cash assistance, food stamps, subsidized housing, and/or health insurance such as Medicaid),
  • have at least 3 new pregnant people per month on average (i.e., enough patient flow to run ROSE), and
  • agree to study procedures. Inclusion criteria were for the clinic itself; once the clinic was included, any pregnant person within the agency could receive ROSE.

Participants were clinic personnel, and they were enrolled within clinic. Their inclusion criteria were:

  • age 18 or older
  • someone chosen by the agency to respond to quarterly survey questions about clinical delivery of ROSE (the "clinical respondent");
  • someone chosen by the agency to respond to quarterly surveys about operational (billing, scheduling) aspects of ROSE delivery (the "operational respondent," which could be the same or a different person than the "clinical respondent");
  • all ROSE facilitators for the agency (who completed self-rated ROSE adherence forms).

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03267563). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search